The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and ...

Patients in England with head and neck cancer will be fast-tracked onto a clinical trial for a "potentially transformative" ...

Jerome Adams, the U.S. Surgeon General under President Trump's first term, is criticizing his administration's cuts to mRNA vaccine research.

Cancer vaccines in development rely on mRNA technology under attack by RFK Jr. “I am concerned that this could bleed over," ...

The mRNA molecule eventually breaks down in the body. The Cleveland Clinic reports that the risks of mRNA vaccines include pain or swelling at the injection site, fever, fatigue, headaches, muscle ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

Kennedy’s newest decision comes amid a string of vaccine pullbacks at the health department in recent months. In May, he said ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...